Literature DB >> 31578213

Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases.

Vincent Cottin1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31578213     DOI： 10.1183/16000617.0109-2019

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN： 0905-9180


× No keyword cloud information.
  14 in total

1.  Hydroxychloroquine on the Pulmonary Vascular Diseases in Interstitial Lung Disease: Immunologic Effects, and Virus Interplay.

Authors:  Jun-Jun Yeh; Shih-Hueh Syue; Yi-Fun Sun; Yi-Ting Yeh; Ya-Chi Zheng; Cheng-Li Lin; Chung Y Hsu; Chia-Hung Kao
Journal:  Biomedicines       Date:  2022-05-31

2.  Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior.

Authors:  Ngu Khine; Dalia Mudawi; Pilar Rivera-Ortega; Colm Leonard; Nazia Chaudhuri; George A Margaritopoulos
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-06-30       Impact factor: 0.670

3.  Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study).

Authors:  Mouhamad Nasser; Sophie Larrieu; Loic Boussel; Salim Si-Mohamed; Fabienne Bazin; Sébastien Marque; Jacques Massol; Françoise Thivolet-Bejui; Lara Chalabreysse; Delphine Maucort-Boulch; Eric Hachulla; Stéphane Jouneau; Katell Le Lay; Vincent Cottin
Journal:  Respir Res       Date:  2021-05-24

4.  The burden of progressive fibrotic interstitial lung disease across the UK.

Authors:  Thomas Simpson; Shaney L Barratt; Paul Beirne; Nazia Chaudhuri; Anjali Crawshaw; Louise E Crowley; Sophie Fletcher; Michael A Gibbons; Philippa Hallchurch; Laura Horgan; Ieva Jakaityte; Thomas Lewis; Tom McLellan; Katherine J Myall; Ryan Miller; David J F Smith; Stefan Stanel; Muhunthan Thillai; Fiona Thompson; Timothy Wallis; Zhe Wu; Philip L Molyneaux; Alex G West
Journal:  Eur Respir J       Date:  2021-07-08       Impact factor: 16.671

5.  Treatment with antifibrotic agents in idiopathic pleuroparenchymal fibroelastosis with usual interstitial pneumonia.

Authors:  Keishi Sugino; Hirotaka Ono; Hiroshige Shimizu; Takeyuki Kurosawa; Keiko Matsumoto; Masahiro Ando; Kiyoshi Mori; Eiyasu Tsuboi; Sakae Homma; Kazuma Kishi
Journal:  ERJ Open Res       Date:  2021-03-01

Review 6.  The Role of Radiology in Progressive Fibrosing Interstitial Lung Disease.

Authors:  Ahmad Abu Qubo; K M Capaccione; Elana J Bernstein; Maria Padilla; Mary Salvatore
Journal:  Front Med (Lausanne)       Date:  2022-01-13

7.  Outcomes and Incidence of PF-ILD According to Different Definitions in a Real-World Setting.

Authors:  Sebastiano Emanuele Torrisi; Nicolas Kahn; Julia Wälscher; Markus Polke; Joyce S Lee; Philip L Molyneaux; Francesca Maria Sambataro; Claus Peter Heussel; Carlo Vancheri; Michael Kreuter
Journal:  Front Pharmacol       Date:  2021-12-17       Impact factor: 5.810

Review 8.  Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.

Authors:  John N Shumar; Abhimanyu Chandel; Christopher S King
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

Review 9.  Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme.

Authors:  Claudia Valenzuela; Sebastiano Emanuele Torrisi; Nicolas Kahn; Manuel Quaresma; Susanne Stowasser; Michael Kreuter
Journal:  Respir Res       Date:  2020-01-06

10.  Phenotypic clusters and survival analyses in interstitial pneumonia with myositis-specific autoantibodies.

Authors:  Yihua Lia; Yali Fana; Yuanying Wanga; Shuqiao Yanga; Xuqin Dua; Qiao Yea
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-01-13       Impact factor: 1.803
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.